We respect your privacy, by clicking 'Subscribe' you will receive our e-newsletter, including information on Podcasts, Webinars, event discounts, online learning opportunities and agree to our User Agreement. You have the right to object. For further information on how we process and monitor your personal data click here.

2018年2月8日 · In 2016, Quintiles, the world’s largest provider of product development and integrated healthcare services and IMS Health, a leading global information and technology services company merged in a deal worth $9 billion. The merged company was named Quintiles IMS, offering an end-to-end clinical and commercial package to pharma clients.

2022年5月20日 · Founded in 1982, IQVIA is an American multinational company formed through the merger of Quintiles, a leading provider of product development and integrated healthcare services, and IMS Health, a global information and technology services company. The latter has enabled company to have a strong focus on digital solutions and analytics.

2010年9月3日 · The following interviews are part of a Five-Part Series on Marketing Excellence, which draws on landmark IMS research on more than 3,000 new product launches and analysis of 50 in-line brands spanning 10 chronic retail markets. Each offers insights from an IMS expert on best practices for a different aspect of launch and brand management.

2011年1月27日 · This follows a strong two years which saw the category contribute 17 percent of global pharmaceutical sales in the 12 months leading to March 2009, according to IMS Health. Figures released from EvaluatePharma in the same year predicted by 2014 seven of the top ten drugs will be biologics.

2011年5月17日 · Biosimilars, also referred to as Follow-on Biologics, is a term used to describe officially-approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Biosimilars are also referred to as subsequent entry biologics (SEBs) in Canada. Similar biological medicinal products are often called ...

Join us at the Temperature Control & Logistics North American Summit as we cut through the complexity to identify which approaches will work for you, bringing genuine value to your supply chain, your business, and your patients. We have built a program around the unique needs of medium-to-large pharmaceutical manufacturing and small-to-medium biotechnology companies, with bespoke learning ...

2018年12月11日 · Although niche players in the field still have a critical role, key companies continue to dominate, such as Quintiles IMS, Parexel, Charles River Labs, ICON and Covance. Clinical trials can cost upwards of $2.5 billion with timescales spanning over a decade from initial testing to Phase IV and post-market approval.

2011年5月17日 · Global spending on biosimilars is expected to reach $2 billion (£1.3 billion) by 2015, which equates to around 1 percent of global spending on biologics, according to new analysis by IMS Health.

QUESTIONS? Address: IQPC Ltd, 129 Wilton Road, London SW1V 1JZ Telephone: +44 (0) 1135 210 042 Fax: 44 (0) 207 368 9301